Journal of Antimicrobial Chemotherapy, Vol 40, 631-637, Copyright © 1997 by The British Society for Antimicrobial Chemotherapy
N Kato, H Kato, K Tanaka-Bandoh, K Watanabe and K Ueno
The in-vitro activity of AM-1155, a 6-fluoro-8-methoxy quinolone, was
compared with those of temafloxacin, sparfloxacin, tosufloxacin,
ciprofloxacin, ofloxacin and cefmetazole, a cephamycin, against a variety
of anaerobic bacteria. Although AM-1155 demonstrated only modest activity
against the Bacteroides fragilis group and Prevotella bivia (MIC90s > or
=3.13 mg/mL), 76% of the B. fragilis strains tested were inhibited at
AM-1155 concentrations of 0.78 mg/L. AM-1155 was highly active against
Prevotella intermedia, Porphyromonas gingivalis, Fusobacterium spp.,
Clostridium perfringens and Mobiluncus spp. (MIC90s < or =0.39 mg/L). An
in-vivo study using a mixed infection with AM-1155- and
tosufloxacin-susceptible B. fragilis and Escherichia coli strains in rat
granuloma pouch was performed. AM-1155 was effective against both organisms
whereas tosufloxacin was effective only against E. coli. These results
correlated well to the higher pouch levels of AM-1155 than those of
tosufloxacin. Clostridium difficile overgrowth was found in the caecum of
mice treated with ampicillin both 1 and 7 days after 5 days dosing, but not
in AM-1155-treated mice. These results suggest that the clinical efficacy
of AM-1155 against infections involving most anaerobic bacteria except for
the B. fragilis group and P. bivia should be evaluated further.
ORIGINAL ARTICLES
Comparative in-vitro and in-vivo activity of AM-1155 against anaerobic bacteria
Institute of Anaerobic Bacteriology, Gifu University School of Medicine, Japan. nk19@cc.gifu-u.ac.jp
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Tanaka, H. Mikamo, K. Nakao, and K. Watanabe In Vitro Antianaerobic Activity of DX-619, a New Des-Fluoro(6) Quinolone Antimicrob. Agents Chemother., November 1, 2006; 50(11): 3908 - 3913. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Tsurumaki, H. Manda, M. Takei, and M. Hosaka In vitro antimicrobial activity of gatifloxacin against 873 clinical isolates from respiratory tract, urinary tract and surgical infections during 1997-1998 in Japan J. Antimicrob. Chemother., May 1, 2000; 45(5): 685 - 689. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Schaumann, G. Ackermann, B. Pless, M. C. Claros, and A. C. Rodloff In Vitro Activities of Gatifloxacin, Two Other Quinolones, and Five Nonquinolone Antimicrobials against Obligately Anaerobic Bacteria Antimicrob. Agents Chemother., November 1, 1999; 43(11): 2783 - 2786. [Abstract] [Full Text]
|
|
|
|
|
|
G. A. Pankuch, M. R. Jacobs, and P. C. Appelbaum Postantibiotic Effects of Gatifloxacin against Gram-Positive and -Negative Organisms Antimicrob. Agents Chemother., October 1, 1999; 43(10): 2574 - 2575. [Abstract] [Full Text]
|
|
|
|
|
|
L. M. Ednie, M. R. Jacobs, and P. C. Appelbaum Activities of Gatifloxacin Compared to Those of Seven Other Agents against Anaerobic Organisms Antimicrob. Agents Chemother., September 1, 1998; 42(9): 2459 - 2462. [Abstract] [Full Text]
|
|